Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Applied Finance Capital Management LLC

Applied Finance Capital Management LLC increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 69.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,305 shares of the medical research company's stock after acquiring an additional 6,271 shares during the period. Applied Finance Capital Management LLC's holdings in Edwards Lifesciences were worth $1,133,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Harbor Capital Advisors Inc. grew its position in shares of Edwards Lifesciences by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock valued at $824,000 after purchasing an additional 273 shares during the period. Nordea Investment Management AB increased its holdings in shares of Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock valued at $301,355,000 after purchasing an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its holdings in shares of Edwards Lifesciences by 6.7% during the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock worth $355,344,000 after acquiring an additional 300,000 shares during the period. Sivik Global Healthcare LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth about $3,702,000. Finally, Avanza Fonder AB acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $4,845,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 1.6 %

Shares of EW traded up $1.06 on Friday, hitting $69.32. 4,890,092 shares of the stock traded hands, compared to its average volume of 4,907,200. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The stock's 50 day moving average is $71.32 and its two-hundred day moving average is $70.70. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $40.75 billion, a P/E ratio of 9.95, a P/E/G ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the sale, the chief financial officer now owns 30,387 shares of the company's stock, valued at $2,153,526.69. The trade was a 27.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 62,853 shares of company stock worth $4,534,247. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on EW. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research note on Thursday, February 13th. Evercore ISI cut their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Barclays increased their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Finally, Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their price target for the company from $82.00 to $90.00 in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $78.55.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.